, and the 36-month beta value for KZR is at 0.40. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”

The average price suggested by analysts for KZR is $12.50, which is $11.71 above the current market price. The public float for KZR is 58.23M, and currently, shorts hold a 3.77% of that float. The average trading volume for KZR on November 16, 2023 was 490.30K shares.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


KZR) stock’s latest price update

Kezar Life Sciences Inc (NASDAQ: KZR) has seen a rise in its stock price by 1.15 in relation to its previous close of 0.78. However, the company has experienced a -5.47% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-10-04 that Kezar (KZR) falls 10% on the decision to channel resources to one clinical candidate as part of its reprioritization efforts and slash the workforce by 41%.

KZR’s Market Performance

KZR’s stock has fallen by -5.47% in the past week, with a monthly drop of -25.31% and a quarterly drop of -43.04%. The volatility ratio for the week is 13.42% while the volatility levels for the last 30 days are 9.65% for Kezar Life Sciences Inc The simple moving average for the past 20 days is -3.73% for KZR’s stock, with a -70.31% simple moving average for the past 200 days.

Analysts’ Opinion of KZR

Many brokerage firms have already submitted their reports for KZR stocks, with Wells Fargo repeating the rating for KZR by listing it as a “Equal Weight.” The predicted price for KZR in the upcoming period, according to Wells Fargo is $4 based on the research report published on August 11, 2023 of the current year 2023.

KZR Trading at -21.07% from the 50-Day Moving Average

After a stumble in the market that brought KZR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.27% of loss for the given period.

Volatility was left at 9.65%, however, over the last 30 days, the volatility rate increased by 13.42%, as shares sank -19.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.64% lower at present.

During the last 5 trading sessions, KZR fell by -5.47%, which changed the moving average for the period of 200-days by -88.96% in comparison to the 20-day moving average, which settled at $0.8125. In addition, Kezar Life Sciences Inc saw -88.75% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at KZR starting from Morningside Venture Investment, who sale 40,000 shares at the price of $6.88 back on Feb 06. After this action, Morningside Venture Investment now owns 5,447,993 shares of Kezar Life Sciences Inc, valued at $275,320 using the latest closing price.

Morningside Venture Investment, the 10% Owner of Kezar Life Sciences Inc, sale 25,000 shares at $7.15 during a trade that took place back on Feb 03, which means that Morningside Venture Investment is holding 5,487,993 shares at $178,650 based on the most recent closing price.

Stock Fundamentals for KZR

The total capital return value is set at -28.38, while invested capital returns managed to touch -27.39. Equity return is now at value -35.17, with -31.69 for asset returns.

Based on Kezar Life Sciences Inc (KZR), the company’s capital structure generated 7.88 points at debt to equity in total, while total debt to capital is 7.30. Total debt to assets is 7.10, with long-term debt to equity ratio resting at 6.93. Finally, the long-term debt to capital ratio is 6.42.

When we switch over and look at the enterprise to sales, we see a ratio of -28.34, with the company’s debt to enterprise value settled at 0.10. The liquidity ratio also appears to be rather interesting for investors as it stands at 25.98.


In conclusion, Kezar Life Sciences Inc (KZR) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.